- Home
- OXY vs TAK Comparison
OXY vs TAK Comparison
Compare OXY & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OXY | TAK |
|---|---|---|
| Founded | 1920 | 1781 |
| Country | United States | Japan |
| Employees | 10412 | 47455 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.5B | 52.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OXY | TAK |
|---|---|---|
| Price | $57.10 | $16.18 |
| Analyst Decision | Hold | |
| Analyst Count | 21 | 0 |
| Target Price | ★ $57.71 | N/A |
| AVG Volume (30 Days) | ★ 10.2M | 3.0M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | 1.71% | ★ 3.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.12 | $0.16 |
| Revenue Next Year | N/A | $1.22 |
| P/E Ratio | ★ $29.26 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.80 | $12.99 |
| 52 Week High | $67.45 | $18.90 |
Technical Indicators
Market Signals| Indicator | OXY | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 46.92 | 37.62 |
| Support Level | $52.35 | $15.88 |
| Resistance Level | $60.77 | $16.48 |
| Average True Range (ATR) | 1.61 | 0.24 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 48.81 | 30.09 |
Price Performance
Historical ComparisonAbout OXY Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2025, the company reported net proved reserves of 4.6 billion barrels of oil equivalent. Net production averaged 1.4 million barrels of oil equivalent per day in 2025 at a ratio of roughly 74% oil and natural gas liquids and 26% natural gas.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.